These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31116107)

  • 1. Bromodomain and Extra-Terminal domain inhibitors for lymphoid malignancies.
    Bertoni F; Stathis A
    Curr Opin Hematol; 2019 Jul; 26(4):273-280. PubMed ID: 31116107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromodomain inhibitors: what does the future hold?
    Bhattacharya S; Piya S; Borthakur G
    Clin Adv Hematol Oncol; 2018 Jul; 16(7):504-515. PubMed ID: 30067623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms.
    Chen NC; Borthakur G; Pemmaraju N
    Leuk Lymphoma; 2021 Mar; 62(3):528-537. PubMed ID: 33161793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NF-κB signaling activation via increases in BRD2 and BRD4 confers resistance to the bromodomain inhibitor I-BET151 in U937 cells.
    Hishiki K; Akiyama M; Kanegae Y; Ozaki K; Ohta M; Tsuchitani E; Kaito K; Yamada H
    Leuk Res; 2018 Nov; 74():57-63. PubMed ID: 30300821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.
    Pearson AD; DuBois SG; Buenger V; Kieran M; Stegmaier K; Bandopadhayay P; Bennett K; Bourdeaut F; Brown PA; Chesler L; Clymer J; Fox E; French CA; Germovsek E; Giles FJ; Bender JG; Hattersley MM; Ludwinski D; Luptakova K; Maris J; McDonough J; Nikolova Z; Smith M; Tsiatis AC; Vibhakar R; Weiner S; Yi JS; Zheng F; Vassal G
    Eur J Cancer; 2021 Mar; 146():115-124. PubMed ID: 33601323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BET bromodomain inhibitors in leukemia.
    Basheer F; Huntly BJ
    Exp Hematol; 2015 Aug; 43(8):718-31. PubMed ID: 26163798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromodomains: Structure, function and pharmacology of inhibition.
    Ferri E; Petosa C; McKenna CE
    Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications.
    Reyes-Garau D; Ribeiro ML; Roué G
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31581671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting BET bromodomain proteins in cancer: The example of lymphomas.
    Spriano F; Stathis A; Bertoni F
    Pharmacol Ther; 2020 Nov; 215():107631. PubMed ID: 32693114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
    Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
    Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BET inhibitors: a novel epigenetic approach.
    Doroshow DB; Eder JP; LoRusso PM
    Ann Oncol; 2017 Aug; 28(8):1776-1787. PubMed ID: 28838216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BET inhibitors in cancer therapeutics: a patent review.
    Ghoshal A; Yugandhar D; Srivastava AK
    Expert Opin Ther Pat; 2016; 26(4):505-22. PubMed ID: 26924192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic induction of cell death in haematological malignancies by combined phosphoinositide-3-kinase and BET bromodomain inhibition.
    Tinsley S; Meja K; Shepherd C; Khwaja A
    Br J Haematol; 2015 Jul; 170(2):275-8. PubMed ID: 25640480
    [No Abstract]   [Full Text] [Related]  

  • 18. BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer.
    Genta S; Pirosa MC; Stathis A
    Curr Oncol Rep; 2019 Feb; 21(2):13. PubMed ID: 30715616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.
    Boi M; Gaudio E; Bonetti P; Kwee I; Bernasconi E; Tarantelli C; Rinaldi A; Testoni M; Cascione L; Ponzoni M; Mensah AA; Stathis A; Stussi G; Riveiro ME; Herait P; Inghirami G; Cvitkovic E; Zucca E; Bertoni F
    Clin Cancer Res; 2015 Apr; 21(7):1628-38. PubMed ID: 25623213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.
    Chaidos A; Caputo V; Karadimitris A
    Ther Adv Hematol; 2015 Jun; 6(3):128-41. PubMed ID: 26137204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.